

DAFTAR PUSTAKA

- Adham, M., Froelicher, E.S., Batiha, A., dan Ajlouni, K., 2010, Glycaemic control and its associated factors in type 2 diabetic patient in Amman, Jordan, *EMHJ*, **6**, 732-739.
- Ado, M.W., 2012, Identifikasi *Drug Related Problems* pada Pasien Pediatrik di Bangsal Rawat Inap RSUD Abunawas Kendari Periode November 2011-Januari 2012, *Tesis*, Program Pascasarjana Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Ahmad, N.S., Islahudin, F., dan Paraidhatathu, T., 2014, Factor Associated with good glycemic control among patient with type 2 diabetes mellitus, *J Diabetes Invest*, **5**, 563-569.
- Ahren, B., Simosson, E., Larsson, H., Olsson, M. L., Torgeirsson, H., Jansson, P. A., Sandqvist, M., Bahenvolm, P., Efendic, S., Eriksson, J.W., Dickinson, S., Holmes, D., 2002, Emerging Treatment and Technologies : Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes, *Diabetes Care*, **25**(5), 869-875.
- Ali, M.K., Bullard, K.M., Saaddine, J.B., Cowie, C.C., Imperatore, G., dan Gregg, E.W., 2013, Achievement of Goals in U.S. Diabetes Care 1999-2010, *N Engl J Med*, **368**, 1613-1624.
- Al-Mahroos F., Al-Roomi K., dan McKeigue P.M., 2000, Relation of high blood pressure to glucose intolerance, plasma lipid, and educational status in an Arabian Gulf population, *International Journal Of Epidemiology*, **29**, 71-76.
- American Diabetes Association*, 2009, Standard of Medical Care in Diabetes, *Diabetes Care*, volume **32**(suppl. 1), S13-S47.
- American Diabetes Association*, 2012, Standards of medical care in diabetes-2012, *Diabetes Care*, **35**(suppl. 1), S11-S63.
- American Diabetes Association*, 2014, Standard of Medical Care in Diabetes-2014, *Diabetes Care*, **37**(suppl.1), S14-S62.
- American Diabetes Association, 2015, Standards of medical care in diabetes-2015, *Diabetes Care*, **38**(suppl.1), S1-S2.
- Anonim, 2007, *Farmakologi dan Terapi*, UI Press, Jakarta.
- Anonim, 2008, *ISO Farmakoterapi*, PT ISFI Penerbitan, Jakarta.
- Anonim, 2010, Diagnosis and Classification of Diabetes Mellitus, *Diabetes Care*, **33**, 62.

- Anonim, 2011, Medical Guidelines for Clinical for Developing a Diabetes Mellitus Comprehensive Care Plan, *American Association of Clinical Endocrinologist (AACE)*.
- Anonim, 2014, Are You At Risk : Lower Your Risk, <http://www.diabetes.org/are-you-at-risk/lower-your-risk/nonmodifiables.htm#Gender>, 5 Mei 2015.
- Asdie, A.H., 2000, *Patogenesis dan Terapi Diabetes Melitus Tipe 2*, 18-45, Fakultas Kedokteran Univeritas Gadjah Mada, Yogyakarta.
- Barnett, A.H., Bain, S.C., Bouter, P., Karlbers, B., Madibad, S., Jervel, S., Mustonen, J., 2004, Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy, *N ENGL J MED* **351**, 52-61.
- Benowitz, N.L., 2007, *Antihypertensive Agent*, dalam Katzung, B.G., *Basic & Clinical Pharmacology*, 10th edition, 159-182, McGraw-Hill Companies, New York.
- Boucher, 2009, Integrating Food and Medication as A Way of A Life, *Clinical Diabetes*, **27** (4), 129-130.
- Brunton, L., Parker, K.L., Buxton, I., Blumenthal, D.L., 2008, *Manual pharmacology and therapeutic Goodman and Gilman*, The McGraw-Hill, Companies, United States of America.
- Cavanaugh, K.L., 2007, Diabetes Management Issues for Patient With Chronic Kidney Disease, *Clinical Diabetes*, **25** (3), 90-97.
- Centers for Disease Control and Prevention*, 2014, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States 2014, Department of Health and Human Services, Atlanta, GA: U.S.
- Chan, D.C., Chen J.H., Kuo H.K., We C.J., Lu I.S., Chiu L.S., Wu, S.C., 2011, Drug-related problems (DRPs) identified from geriatric medication safety review clinics, *Arh Gerontol Geriatr* 54:168-174 cit Zaman Huri dan Fun Wee, 2013, Drug related problems in type 2 diabetes patient with hypertension: a cross-sectional retrospective study, *BMC Endocrine* **13** : 2.
- Chobanian, A. V., Bakri, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., dan Wright. J.T., 2003, Seventh Report of The Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, *Hypertension*, **42**, 1206-1252.
- Cipolle R.J., Stand L.M., dan Morley P.C., 1998, *Pharmaceutical care Practice*, The McGraw-Hill Companies, New York.

- Cipolle, R.J., Strand, L.M., dan Frakes, M.J., 2007, *Comorbidities and Drug Therapy Problems in Patients with Diabetes*, 1-10, Medication Management System, Inc.
- Cipolle, R.J., Strand, L.M., Frakes, M.J., 2013, *Diabetes: Co-morbidities and Drug Therapy Problems in Patient with Diabetes*, Medication Management System. Inc.
- Cipolle, R.J., Strand, L.M., dan Morley, P.C., 2004, *Pharmaceutical Care Practice :The Clinician's Guide* 2nd edition, McGraw-Hill Medical Publishing Division.
- Craig, K.J., Williams, J.D., Riley, S.G., Smith, H., Owens, D.R., Whorthing, D., Cavill, I., Phillips, A.O., 2005, Anemia and Diabetes in the Absence of Nephropathy, *Diabetes Care*, **28** (5), 1118-1123.
- Depkes, 2005^a, *Pharmaceutical Care untuk Penyakit Diabetes Melitus*, Departemen Kesehatan RI, Jakarta.
- Depkes, 2005^b, *Pharmaceutical Care untuk Penyakit Hipertensi*, Departemen Kesehatan RI, Jakarta.
- Deray, G., Heartier, A., Grimaldi, A., Launay, V.V., Isnard, B.C., 2004, Anemia and Diabetes, *Am J Nephrol*, **24** (2), 522-526.
- DeWitt, D.E., dan Hirsch, I.B., 2003, Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus, *JAMA*, **389** (17), 2254-2271.
- Dincer, H.E., Dincer, A.P., dan Levinson, D.J., 2002, Asymptomatic hyperuricemia: To treat or not to treat, *Cleveland Clin Jour of Med*, **69** (8), 594-602.
- DiPiro, C.V., 2012, *Anemias*, dalam Wells, B.G., DiPiro, J.T., Schwinghammer, T.C., *Pharmacotherapy Handbook*, 8th edition, 1496-1592, Mc Graw Hill, New York.
- DiPiro, J.T., Wells, B.G., Schwinghammer, T.L., DiPiro, C.V., 2009, *Pharmacotherapy handbook Seven Edition*, The McGraw-Hill Companies, United States of America.
- Dowling, T.C., dan Comstock, T.J., 2009, *Quantification of Renal Function*, dalam DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., *Pharmacotherapy A Pathophysiologic Approach*, 6th edition, 761-780, McGraw-Hill, New York.
- Eid M., Mafauzy M., dan Faridah A.R., 2004, Non-Achievement of Clinical Targets in Patient With Type 2 Diabetes Melitus, *Med J Malaysia*, **59**, 177-184.

- Epstein, M., dan Sowers J.R., 1992, Diabetes mellitus and hypertension, *Hypertension*, **19**, 403-418.
- Ernst F.R., dan Grizzle A.J., 2001, Drug-related morbidity and mortality: updating the cost-of-illness model, *J Am Pharm Assoc* **41** (2): 192-199 cit Zaman Huri dan Fun Wee, 2013, Drug related problems in type 2 diabetes patient with hypertension: a cross-sectional retrospective study, *BMC Endocrine* **13**, 1-12.
- European Society of Cardiology*, 2000, Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patient, *European Hearth Journal*, **21**, 2-7.
- Fillenbaum G., Pieper C., Cohen H., Comoni-Huntley J., Guralnik J., 2000, Comorbidity of five chronic health condition in elderly community resident: determinant and impact on mortality, *J Gerontol A Biol Sci Med Sci*, **55**, M84-89.
- Fishbane, S., 2010, The role of erythropoiesis-stimulating agents in the treatment of anemia, *Am J Manag Care*, **16**, S67-73.
- Grundy, S.M., Becker, D., Clark, L.T., Cooper, R.S., Denke, M.A., Howard, W.M., Hunnigake, D.B., Illingworth, D.R., Luepker, R.V., McBride, P., McKenney, J.M., Pasternak, R.C., Stone, N.J., Horn, L.V., 2000, Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), *Circulation*, **17**, 3157-3373.
- Gunar, S., dan Rosa, L.G., Clinical pharmacy and activities in chronic kidney disease and end-stage renal disease patient: A systematic literature review, *BioMed Central Nephrol*, **12** (35), 1-12.
- Hassing L.B., Havet, S.M., Nilsson, S.E., Berg, S., Pedersen, N.L., McClearn, G., Johanson, B., 2004, Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study, *Age and Ageing*, **33**, 355-361.
- Hermann, L.S., Schersten, B., Bitzeh, P.O., Kjellstrom, T., Lindgarge, F., Melander, A., 1994, Therapeutic Comparison of Metformin and Sulfonylurea Alone and in Various Combination, *Diabetes Care*, **17** (10), 1100-1110.
- Hoffman, B.B., 2006, *Therapy of Hypertension*, dalam Brunton, L.L., Lazo, J.S., Parker, K.L., *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11th edition, McGraw-Hill, New York.
- Huri, H.Z dan Hoo F.W, 2013, Drug related problems in type 2 diabetes patient with hypertension: a cross-sectional retrospective study, *BMC Endocrine* **13**, 1-12.

- James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Himmelfarb, C.D., Handler, J., Lackland, D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., Smith, S.C., Svetey, L.P., Taler, S.J., Townsend, R.R., Wright, J.T., Narva, A.S., Ortis, E., 2013, 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adult Report From the Panel Members Appointed to the Eight Joint National Committee (JNC-8), American Medical Association, *JAMA*, E1-E14.
- Jellinger, P.S., Smith, D.A., Mehta, A.E., Garduño, Handelsman, Y., Rodbard, H.W., Shepherd, M.D., Selbel, J.A., 2012, American Association of Clinical Endocrinologists Guideline for Management of Dyslipidemia and Prevention of Atherosclerosis, *Endocr Pract*, **18** (Suppl. 1), 1-78.
- Karen, L. W., dan Stewart, R. D., 2008, Pharmacologic Management of Hypertension in Patient with Diabetes, *Am Fam Physician* **78** (11), 1277-1282.
- KDIGO (Kidney Disease Improving Global Outcome), 2012, Clinical Practice Guideline for Anemia In Chronic Kidney Disease, *Journal of the International Society of Nephrology*, **2** (4), 279-331.
- Kearney, P. M., M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton dan J. He, 2005, Global burden of hypertension: analysis of worldwide data, *Lancet* **365**, 217-223.
- Keith, G. T., Anthony, D., Vivian, F., Tan, M. H., 2007, Spectrum of liver disease in type 2 diabetes and the management of patient with diabetes and liver disease, *Diabetes Care*, **30** (3), 734-743.
- Kemenkes, 2012, *Buletin Jendela Data dan Informasi Kesehatan: Penyakit Tidak Menular*, Semester II, Kementerian Kesehatan RI, Jakarta.
- Kemenkes, 2013, *Riset Kesehatan Dasar Riskesdas 2013*, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, Jakarta.
- Kroon, L.A. dan Williams, C., 2012, *Diabetes Mellitus*, dalam: Alldredge, B.K., Corelli, R.L., Erns, M.E. (Eds), *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*, Lippincott Williams & Wilkins, Philadelphia, pp. 1255.
- Kurniawan, I., 2010, Diabetes Melitus Tipe 2 pada Usia Lanjut, *Maj Kedokt Indon*, **60** (12), 576-584.
- Lacy, L.F., Armstrong, L.L., Goldman, M.P., Lance. L.L., 2009, *Drug Information Handbook A Comprehensive Resource for All Clinicians and Healthcare Professional*, 17th edition, Lexi-comp.Inc, Ohio.
- Lucas, C.P., Estigarriba J.A., Darga L.L., dan Reaven G.M., 1985, Insulin and blood pressure in obesity, *Hypertension*, **7**, 702-706.

- Magaji, V., dan Johnston, J.M., 2011, Inpatient Management of Hyperglycemia and Diabetes, *Clinical Diabetes*, **29** (1), 3-7.
- Mangesha, A.Y., 2007, Hypertension and related risk factors in type 2 diabetes mellitus (DM) patient in Gaborone City Council (GCC) clinics, Gaborone, Botswana, *African Health Science*, **7** (4), 244-245.
- Mannuccini, E., Monami, M., Marchionni N., 2009, Short-acting insulin analogues vs regular human insulin in type 2 diabetes : a meta-analysis, *Journal Compilation*, **11**, 53-59.
- Mansjoer, A., Triyanti, K., Savitri, R., Wardhani, W.I., dan Setiowulan, W., 1999, *Kapita Selekt Kedokteran*, Edisi III, Jilid Pertama, 518-523, Media Aesculapius, Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Mayfield, J., 1998, Diagnosis and Classification of Diabetes Mellitus : New Criteria, *Am Fam Physician*, **58** (6), 1355-1362.
- Medicines and Healthcare Product Regulatory Agency, 2007, Ketoprofen and ketorolac: gastrointestinal risk, <https://www.gov.uk/drug-safety-update/ketoprofen-and-ketorolac-gastrointestinal-risk>, 12 Mei 2015.
- Meneghini, L.F., 2009, Early Insulin Treatment in Type 2 Diabetes, *Diabetes Care*, volume, **2** (supl 2), S266-S269.
- Mohebbi, L., dan Hesch, K, 2009, Stress ulcer prophylaxis in the intensive care unit, *Proc (Bayl Univ Med Cent)*, **22** (4), 373-376.
- Moura, C.S., Acurcio F.A., Belo N.O., 2009, Drug-drug interaction associated with length of stay and cost hospitalization, *J Pharm Pharm Sci*, **12**(3):266-272 cit Zaman Huri dan Fun Wee, 2013, Drug related problems in type 2 diabetes patient with hypertension: a cross-sectional retrospective study, *BMC Endocrine*, **13**, 1-12.
- Munger, M.A., Polipharmacy and combination therapy in the management of hypertension in elderly patient with Co-morbid diabetes mellitus, *Drug Aging* **27**(11):871-883 cit Zaman Huri dan Fun Wee, 2013, Drug related problems in type 2 diabetes patient with hypertension: a cross-sectional retrospective study, *BMC Endocrine*, **13**, 1-12.
- Nathan, D.M., Buse, J.B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B., 2009, Medical Management of Hyperglycemia in Type 2 Diabetes : A Consensus Algorithm for the Initiation and Adjustment of Therapy, *Diabetes Care*, **52**, 14-30.
- NICE, 2012, Headache: Diagnosis and management of headaches in young people and adults, *NICE Clinical Guideline*, **150**, 1-38.

- Niquille A., dan Buqnon O., 2010, Relationship between drug-related problems and helath outcomes: a cross-sectional study among cardiovascular patient, *Pharmacy World & Science*, **32**, 512-519.
- NKF (National Kidney Fondation), 2007, *Diabetes and Chronic Kidney Disease Stage 1-4*, National Kidney Fondation. Inc, New York.
- Oster, J.R., Materson, B.J., dan Epstein, M., 1990, Diabetes mellitus and hypertension, *Cardiovascular Risk Factors*, **1**, 25-46.
- Ozougwu, J.C., Obimba, K.C., Belonwu, C.D., Unakalamba, C.B., 2013, The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus, *J. Physiol.Pathiphysiol*, **4** (4), 46-57.
- Pablos-Velasco, P.D., Parhofer, K.G., Bradley, C., Eschwege, E., Frederick, L.G., Maheux, P., Wood, L., and Simon, D., 2014, *Clin Endocrinol*, **80**, 47-56.
- Perkeni, 2006, *Konsensus Pegelolaan dan Pencegahan Diabetes Melitus tipe 2 di Indonesia*, 4, 17-24, dan 30-32, Perkumpulan Endokrinologi Indonesia.
- Perkeni, 2011, *Konsensus Pengendalian dan Pencegahan Dabetes Melitus Tipe 2 di Indonesia*, Perkumpulan Endokrinologi Indonesia.
- Perwitasari, D.A., 2006, Pola Pengobatan Hipertensi dan Diabetes Melitus Tipe 2 pada Pasien Geriatrik R.S. Dr. Sardjito Jogjakarta, *Majalah Farmasi Indonesia*, **5** (1), 61-68.
- Petznick, A., 2001, Insulin Management of Type 2 Diabetes Mellitus , *Am Fam Physician* **84** (2), 183-190.
- Pitte, J. D., dan Kerr, E.A., 2006, The Impact of Comorbid Chronic Condition on Diabetes Care, *Diabetes Care*, **29** (3), 725-731.
- Qian, Y., Lin, Y., Zhang, T., Chen, F., Zhang, Y., Luo, S., Shen, H., 2010, The characteristic of impaired fasting glucose associated with obesity and dyslipidemia in a Chinese population, *BMC Pubic Health*, **10**, 139.
- Sarifah, S., 2014, Faktor-faktor yang mempengaruhi masih tingginya kadar gula darah pasien diabetes meellitus yang menjalani terapi diabetes mellitus di Poliklinik Penyakit Dalam RSUP dr. Sardjito Yogyakarta, *Jurnal Kesehatan Profesi Profesional Islami*, **7**, 21-29.
- Saseen, J.J., dan Carter, B.L., 2005, *Hypertension*, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M., *Pharmacoteraphy a Pathophysiological Approach*, 6th Edition, 185-217, Appleton and Lange, Stamford Connecticut.
- Schutta, M.H., 2007, Diabetes and Hypertension: Epidemiology of the Relationship nd Pathophysiology of Factor Associated With These Comorbid Condition, *JCMC Spring*, **2**:124-130.

- Schwinghammer, T.L., 2000, *Hypertension* in Dipiro, et al. *Parmaoterapy Handbook, 2rd Edition*, 94-113, Appleton and Lange, Stamford.
- Schwinghammer, T.L., 2012^a, *Dyslipidemia*, dalam Wells, B.G., Dipiro, J.T., Schwinghammer, T.L., DiPiro, C.V., *Pharmacotherapy Handbook*, 8th edition, 356-413, McGraw-Hill, New York.
- Schwinghammer, T.L., 2012^b, *Gout and Hyperuricemia*, dalam Wells, B.G., Dipiro, J.T., Schwinghammer, T.L., DiPiro, C.V., *Pharmacotherapy Handbook*, 8th edition, 31-64, McGraw-Hill, New York.
- Shaw, J.E., Sicree, R.A., dan Zimmet, P.Z., 2010, Global estimate of the prevalence of diabetes for 2010 and 2030, *Diabetes Res Clin Pract*, **87**, 4-14.
- Struijs, J. N., Baan, C. A., Schellevis, F. G., Westert, G.P., Bos, G. A. M., 2006, Comorbidity in Patient with Diabetes Mellitus: Impact on Medical Health Care Utilization, *BMC Health Care Services Research*, **6**, 84.
- Tatro, D.S., 2009, *Drug Interaction Facts*, Wolters Kluwers Health. Inc, California.
- Thomas, M.C., MacIsaac, R.J., Tsalamandris, C., Power, D., Jerume, G., 2003, Uncategorized Anemia in Patient With Diabetes, *Diabetes Care*, **26** (4), 1164-1169.
- Tjay, H.T., dan Rahardja, K., 2007, *Obat-Obat Penting*, PT Elex Media Komputindo Gramedia, Jakarta.
- Tosi, F., Muggeo, M., Brun, E., Spiazzi, E., Perobelli, L., Zarolin, E., Gori, M., Coppini, A., Maghetti, P., 2003, Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus : a randomized, double-blind, comparative studies, *Metabolism*, **52** (7), 862-867.
- Triplitt, C. L., Reasner, C. A., Isley, W. L., 2005, *Diabetes Mellitus*, dalam Dipiro, J.T., Tabert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., Posey, L. M., (Eds), *Pharmacoterapy A Pathophysiological Approach*, 6th edition, 1207-1208, 1214-1226, Mc Graw Hill, New York.
- Viberti, G., dan Wheeldon, N.M., 2002, Microalbuminuria Reduction With Valsartan in Patient With Type 2 Diabetes Mellitus, *Circulation*, **106**, 672-678.
- Weiss, A., Michael, Martha, F.M., 2009, In the Beginning: Setting the Stage for Effective Diabetes Care, *Clinical Diabetes*, **27** (2), 150-151.

Wells, B.G., Dipiro, J.T., Schwinghammer, T.L., dan DiPiro, C.V.,
Pharmacotherapy Handbook, 8th edition, 31-64, McGraw-Hill, New
York.

Winblad, B., 2005, Piracetam: A Review of Pharmacological Properties and
Clinical Uses, *CNS Drug Reviews*, **11**(2), 169-182.